Aromatase inhibitors: effective endocrine therapy in the early adjuvant setting for postmenopausal women with hormone-responsive breast cancer

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 20, Issue SUPPL. 1, 2006, Pages

  Mauriac, Louis ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

adjuvant endocrine therapy; aromatase inhibitors; postmenopausal women

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; PLACEBO; TAMOXIFEN;

ADJUVANT THERAPY; ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FRACTURE; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE; MYALGIA; POSTMENOPAUSE; PREDICTION; PROGNOSIS; REVIEW; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; VAGINA BLEEDING;

EID: 33845305763     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2006.10.003     Document Type: Review

References (42)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365 (2005) 1687-1717
2. Fisher B., Dignam J., Bryant J., et al. Five years versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. Journal of the National Cancer Institute 88 (1996) 1529-1542
3. Saphner T., Tormey D.C., and Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. Journal of Clinical Oncology 14 (1996) 2738-2746
4. Lønning P.E. Aromatase inhibition for breast cancer treatment. Acta Oncologica (Stockholm, Sweden) 35 supplement 5 (1996) S38-S43
5. Buzdar A.U., Robertson J.F., Eiermann W., et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer 95 (2002) 2006-2016
6. Dombernowsky P., Smith I., Falkson G., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology 16 (1998) 453-461
7. Kaufmann M., Bajetta E., Dirix L.Y., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. Journal of Clinical Oncology 18 (2000) 1399-1411
8. Buzdar A., Jonat W., Howell A., et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. Journal of Clinical Oncology 14 (1996) 2000-2011
9. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. Journal of Clinical Oncology 21 (2003) 2101-2109
10. Bonneterre J., Buzdar A., Nabholtz J.M., et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92 (2001) 2247-2258
11. Paridaens R., Dirix L., Lohrisch C., et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Annals of Oncology 14 (2003) 1391-1398
12. Buzdar A., Douma J., Davidson N., et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. Journal of Clinical Oncology 19 (2001) 3357-3366
13. Eiermann W., Paepke S., Appfelstaedt J., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Annals of Oncology 12 (2001) 1527-1532
14. Smith I.E., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. Journal of Clinical Oncology 23 (2005) 5108-5116
15. Baum M., Budzar A.U., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139 Erratum in: Lancet 2002; 360: 1520
16. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
17. Arimidex Prescribing Information. www.arimidex.com Accessed 11 July 2006
18. Howell A., and on behalf of the ATAC Trialists' Group. ATAC ('Arimidex', Tamoxifen, Alone or in Combination) completed treatment analysis: anastrozole demonstrates superior efficacy and tolerability compared with tamoxifen. Breast Cancer Research and Treatment 88 (2004) S5. (abstract 1). Available online: http://www.sabcs.org/SymposiumOnline/index.asp#webcast
19. Dowsett M., Cuzick J., Wale C., et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. Journal of Clinical Oncology 23 (2005) 7512-7517
20. Thürlimann B., and on behalf of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The New England Journal of Medicine 353 (2005) 2747-2757
21. Viale G., Regan M., Dell'Orto P., et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Research and Treatment 94 supplement 1 (2005) (abstract 44)
22. Camp R.L., Dolled-Filhart M., King B.L., et al. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Research 63 (2003) 1445-1448
23. De Placido S., De Laurentiis M., Carlomagno C., et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clinical Cancer Research 9 (2003) 1039-1046
24. Ellis M.J., Coop A., Singh B., et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Research 63 (2003) 6523-6531
25. Coombes R.C., Hall E., Gibson L.J., et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. The New England Journal of Medicine 350 (2004) 1081-1092 Erratum in: The New England Journal of Medicine 2004; 351: 2461
26. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. Journal of Clinical Oncology 23 (2005) 5138-5147
27. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
28. Jakesz R., Gnant M., Greil R., et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. Breast Cancer Research and Treatment 94 supplement 1 (2005). (abstract 13). Available online: http://www.sabcs.org/SymposiumOnline/index.asp#webcast
29. Mauriac L., Keshaviah A., Debled M., et al. Predictors of early recurrence in postmenopausal women with hormone receptor positive breast cancer in the BIG 1-98 trial. EJC Supplements 4 (2006) 111. http://www.ibcsg.org/public/documents/pps/trial_18-98/EBCC_Mauriac_BIG1-98.ppt Available online:
30. Goldhirsch A., Glick J.H., Gelber R.D., et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Annals of Oncology 16 (2005) 1569-1583
31. Rieber A.G., and Theriault R.L. Aromatase inhibitors in postmenopausal breast cancer patients. Journal of the National Comprehensive Cancer Network 3 (2005) 309-314
32. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. Journal of Clinical Oncology 23 (2005) 619-629
33. Perez E.A. The balance between risks and benefits: long-term use of aromatase inhibitors. European Journal of Cancer Supplement 4 9 (2006) 16-25
34. Herrington D.M., and Klein K.P. Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Womens Health Issues 11 (2001) 95-102
35. Braithwaite R.S., Chlebowski R.T., Lau J., et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. Journal of General Internal Medicine 18 (2003) 937-947
36. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. Journal of the National Cancer Institute 97 (2005) 1262-1271
37. Ramaswamy B., and Shapiro C.L. Osteopenia and osteoporosis in women with breast cancer. Seminars in Oncology 30 (2003) 763-775
38. Brufsky A., Harker W., Beck J., et al. Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): 12 mos BMD results of the Z-FAST trial. Journal of Clinical Oncology 23 (2005) 12s (abstract 533)
39. Bundred N., Campbell I., Coleman R., et al. Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study). European Journal of Cancer Supplement 4 (2006) 48 (abstract 12)
40. Fallowfield L., Cella D., Cuzick J., et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. Journal of Clinical Oncology 22 (2004) 4261-4271
41. Fallowfield L.J., Bliss J.M., Porter L.S., et al. Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. Journal of Clinical Oncology 24 (2006) 910-917
42. Whelan T.J., Goss P.E., Ingle J.N., et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. Journal of Clinical Oncology 23 (2005) 6931-6940